VTE market set to hit $2.85 million sales by 2026; report

7 June 2017

The venous thromboembolism (VTE) space across the seven major markets of the USA, France, Germany, Italy, Spain, the UK and Japan, is set to rise from $1.95 billion in 2016 to around $2.85 billion by 2026, representing a strong compound annual growth rate (CAGR) of 3.87%.

According to research and consulting firm GlobalData, the major drivers of the rise in market value include an increase in patient uptake of novel oral anticoagulants (NOACs), the launch of Portola Pharmaceuticals’ (Nasdaq: PTLA) betrixaban for extended-duration prophylaxis in acute medically ill patients, and an increase in the global prevalence of VTE.

GlobalData believes that the most prominent wave of VTE sales increases will come from the NOAC class, which is expected to peak at $1.04 billion in global sales by 2022, reflecting a 10-year CAGR of 3.91% by 2026, despite the generic erosion of several key players.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK